![](https://monteverdelaw.com/wp-content/uploads/case-logo/harpoon-therapeutics-inc.png)
Harpoon Therapeutics, Inc. (Nasdaq: HARP), relating to its proposed sale to Merck. Under the terms of the agreement, HARP shareholders will receive $23.00 in cash per share they own.
Harpoon Therapeutics, Inc. (Nasdaq: HARP), relating to its proposed sale to Merck. Under the terms of the agreement, HARP shareholders will receive $23.00 in cash per share they own.